Kairos Pharma, Ltd.
KAPA · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $160 | $160 | $160 | $98 |
| Gross Profit | -$160 | -$160 | -$160 | -$98 |
| % Margin | – | – | – | – |
| R&D Expenses | $414 | $82 | $87 | $183 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,769 | $1,472 | $324 | $1,662 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,183 | $1,554 | $411 | $1,845 |
| Operating Income | -$2,343 | -$1,714 | -$571 | -$1,943 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$260 | -$98 | -$479 | -$202 |
| Pre-Tax Income | -$2,603 | -$1,812 | -$1,050 | -$2,145 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,603 | -$1,812 | -$1,050 | -$2,145 |
| % Margin | – | – | – | – |
| EPS | -0.23 | -0.17 | -0.1 | -0.17 |
| % Growth | -35.3% | -70% | 41.2% | – |
| EPS Diluted | -0.23 | -0.17 | -0.1 | -0.17 |
| Weighted Avg Shares Out | 11,356 | 10,382 | 10,236 | 12,842 |
| Weighted Avg Shares Out Dil | 11,356 | 10,383 | 10,237 | 12,842 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $859 | $98 | $479 | $202 |
| Depreciation & Amortization | $160 | $160 | $160 | $98 |
| EBITDA | -$1,584 | -$1,554 | -$411 | -$1,845 |
| % Margin | – | – | – | – |